NCT03975114 - A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) | Biotech Hunter

Enrollment

460

Participants

Timeline

Start Date

December 20, 2018

Primary Completion Date

December 31, 2023

Study Completion Date

June 30, 2024

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Chemotherapy

Any approved first line chemotherapy regimen at Investigators' choice

DRUG

Durvalumab

Durvalumab 1500 mg iv Q4w until progressive or unacceptable toxicity or patient's refusal

DRUG

Tremelimumab

Tremelimumab 75 mg iv Q4w for 4 administrations (4 months)

Trial Locations (1)

RECRUITING

Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli